The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

Slides:

Advertisements

Similar presentations

Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.

Advertisements

Subgroup Placebo n/N (%) Serelaxin n/N (%)Favours placeboFavours serelaxin Odds ratio Estimate (95%CI) Interaction P value Total population150/580 (25.9)156/581.

Sex- and Gender-Related Risk Factor Burden in Patients With Premature Acute Coronary Syndrome Jin Choi, MSc, Stella Styliani Daskalopoulou, MD, MSc, PhD,

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Mariell.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Fig ACCF/AHA Guideline for the management of heart failure

Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience John J. Sim, MD, Joel Handler, MD, Steven.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Management of mitral regurgitation. See legend for Fig

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

Kiran Sidhu, MD, FRCPC, Anthony Tang, MD, FRCPC

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure Justin A. Ezekowitz, MBBCh, Eileen O'Meara,

Robert Roberts, MD, FRCPC, MACC Canadian Journal of Cardiology

Volume 1: Chronic Kidney Disease

by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation Ratika Parkash, MD, MSc, François Philippon,

2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary

Discharge Heart Rate and Mortality after Acute Myocardial Infarction

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Developed in Collaboration With The American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,

2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure Justin A. Ezekowitz, MBBCh, Eileen O'Meara,

Diabetes Mellitus and Heart Failure

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

Clyde W. Yancy et al. JACC 2017;70:

Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)

Chapter 4: Cardiovascular Disease in Patients with CKD

The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure Robert S. McKelvie, MD,

Sandra Lauck, RN, PhD, Dion Stub, MD, PhD, John Webb, MD

Step Care Therapy for Hypertension in Diabetic Patients

Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines Matthew Bennett, MD (Co-Chair),

Predictors of 30-day hospital readmission after coronary artery bypass

The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,

Gaurav A. Upadhyay, MD, Jonathan S. Steinberg, MD Heart Rhythm

Sexual Activity and Chronic Heart Failure

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures Gyorgy Frendl,

Presentation, Diagnosis, and Medical Management of Heart Failure in Children: Canadian Cardiovascular Society Guidelines Paul F. Kantor, MBBCh, Jane.

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Fig. 2. Evidence-based medication prescriptions

Systematizing Inpatient Referral to Cardiac Rehabilitation 2010: Canadian Association of Cardiac Rehabilitation and Canadian Cardiovascular Society Joint.

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Ethnic and racial disparities in cardiac resynchronization therapy

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Marta Kelava, MD, Michael Robich, MD, MSPH, Penny L

Volume 15, Issue 1, Pages (January 2018)

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Jennifer Tjia, MD, MSCE, Jeroan Allison, MD, Jane S

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

Volume 8, Issue 1, Pages (January 2011)

Volume 8, Issue 3, Pages (March 2011)

Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH CJC Open

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation.

Erratum Canadian Journal of Cardiology

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management Anne M. Gillis, MD, FRCPC, Atul Verma, MD, FRCPC, Mario.

EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART.

Rick A. Nishimura et al. JACC 2017;70:

The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization

Mobile Medicine: Digital Dynamo or Virtual Vaporware

β-Blocker Use for the Stages of Heart Failure

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Presentation transcript:

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS, FRCPC, FACC, Justin A. Ezekowitz, MBBCh, MSc, FRCPC, Karen Harkness, RN, PhD, George A. Heckman, MD, FRCPC, Simon Kouz, MD, FRCPC, Marie-Hélène Leblanc, MD, FRCPC, Gordon W. Moe, MD, FRCPC, Eileen O’Meara, MD, FRCPC, Howard Abrams, MD, FRCPC, Anique Ducharme, MD, FRCPC, Adam Grzeslo, MD, CCFP, Peter G. Hamilton, MBBCh, FRCPC, Sheri L. Koshman, PharmD, ACRP, Serge Lepage, MD, FRCPC, Michael McDonald, MD, FRCPC, Robert McKelvie, MD, PhD, FRCPC, Miroslaw Rajda, MD, FRCPC, Elizabeth Swiggum, MD, FRCPC, Sean Virani, MD, FRCPC, Shelley Zieroth, MD, FRCPC Canadian Journal of Cardiology Volume 32, Issue 3, Pages 296-310 (March 2016) DOI: 10.1016/j.cjca.2015.06.019 Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions

Figure 1 Recommended initial referral wait time and follow-up frequency. ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ACS, acute coronary syndrome; AHA/ACC, American Heart Association/American College of Cardiology; COPD, chronic obstructive pulmonary disease; D/C, hospital discharge; ER, Emergency Department; FC, functional class; HF, heart failure; hrs, hours; ICD, implantable cardioverter defibrillator; MI, myocardial infarction; NYHA, New York Heart Association. Canadian Journal of Cardiology 2016 32, 296-310DOI: (10.1016/j.cjca.2015.06.019) Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions

Figure 2 Therapeutic approach to patients with HF and reduced ejection fraction. ACE, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; bpm, beats per minute; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SR, sinus rhythm. Canadian Journal of Cardiology 2016 32, 296-310DOI: (10.1016/j.cjca.2015.06.019) Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions